Breast Cancer

Latest News

Trastuzumab Deruxtecan Provides Long-Term Survival Benefit for HER2+ Metastatic Breast Cancer
Trastuzumab Deruxtecan Provides Long-Term Survival Benefit for HER2+ Metastatic Breast Cancer

May 22nd 2024

Compared with physician’s choice of treatment, trastuzumab deruxtecan exhibited superior long-term survival and response rates in patients with HER2-positive breast cancer.

Atezolizumab Plus Chemo Did Not Improve Survival in TNBC
Atezolizumab Plus Chemo Did Not Improve Survival in TNBC

May 21st 2024

MRI Guidance Can Tailor Neoadjuvant Chemo for HR-/HER2+ Breast Cancer
MRI Guidance Can Tailor Neoadjuvant Chemo for HR-/HER2+ Breast Cancer

May 14th 2024

TIL Presence in TNBC May Indicate Improved Survival
TIL Presence in TNBC May Indicate Improved Survival

May 13th 2024

USPSTF Recommends Women Begin Undergoing Mammograms at 40 Years Old
USPSTF Recommends Women Begin Undergoing Mammograms at 40 Years Old

May 3rd 2024

Video Series
Video Interviews
Podcasts
The Vitals
Oncology Nursing News
Are Hearing Tests Necessary For Adult Cancer Survivors?
Sarah Donahue Highlights Destiny-04 Trial Takeaways for Patients With HR+, HER2-Low Metastatic Breast Cancer
Key Advances in Cancer Survivorship Toxicity Management
Loyda Braithwaite Discusses Evolving Treatment Options in HR+ Breast Cancer
Latest CME Events & Activities

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician

View More

Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

23rd Annual International Congress on the Future of Breast Cancer® East

July 19-20, 2024

Register Now!

Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

42nd Annual Miami Breast Cancer Conference®

March 6 - 9, 2025

Register Now!

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

View More

More News

© 2024 MJH Life Sciences

All rights reserved.